Market Place
Sourcing Support
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
19 Aug 2024 //
GLOBENEWSWIRE
Ipsen announces U.S. FDA submission acceptance of its sN DA for Onivyde
14 Jun 2023 //
GLOBENEWSWIRE
Edison Oncology Announces Presentation of Two Scientific Posters at AACR Meeting
20 Apr 2023 //
PR NEWSWIRE
Ipsen`s Onivyde turns in positive results in pancreatic cancer
21 Jan 2023 //
FIERCE PHARMA
RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial
14 Dec 2022 //
PRNEWSWIRE
Ipsen to File sNDA for Pancreatic Cancer Drug Following Positive PhIII Results
10 Nov 2022 //
BIOSPACE
Onivyde® Regimen Demonstrated Significant Improvement in Overall Survival
09 Nov 2022 //
BUSINESSWIRE
Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde
04 Aug 2022 //
PHARMAPHORUM
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde
03 Aug 2022 //
BUSINESSWIRE
An anticancer drug made to increase efficacy and decrease side effects
23 May 2022 //
ARIRANG
EpicentRx begins Phase I trial of paediatric CNS tumour treatment
25 Feb 2022 //
CLINICALTRIALSARENA
PharmaMar, Jazz Announce Initiation of Confirmatory Phase 3 Trial of Zepzelca
11 Dec 2021 //
PRNEWSWIRE
Michael Landon’s daughter urges testing in pancreatic cancer PSA
08 Nov 2021 //
FIERCEPHARMA
Ipsen poaches Novartis vet Mari Scheiffele
11 Oct 2021 //
FIERCEPHARMA
FDA expands Lilly`s Erbitux label with Braftovi to treat metastatic CRC
30 Sep 2021 //
PHARMABIZ
Cardiff Announces 1st Patient Dosed in Ph2 Trial of Onvansertib+ Irinotecan+5-FU
08 Jun 2021 //
BIOSPACE
Salarius Pharma Presents New Research Data at ASCO 2021 Annual Meeting
07 Jun 2021 //
GLOBENEWSWIRE
Enforcement Report - Week of March 3, 2021
03 Mar 2021 //
FDA
Eugia Pharma`s Generic Irinotecan Hydrochloride Receives Approval in US
04 Nov 2020 //
FDA
Ipsen presents Ph I/II clinical data evaluating liposomal irinotecan (Onivyde®)
30 Jun 2020 //
BUSINESSWIRE
Enforcement Report - Week of June 24, 2020
24 Jun 2020 //
FDA
Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®)
17 Jun 2020 //
PRESS RELEASE
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan
17 Jun 2020 //
BUSINESSWIRE
Success for Enhertu in Phase II gastric cancer trial
28 Jan 2020 //
PHARMA TIMES
After exiting troubled Merrimack, former CEO becomes new chief at Yumanity
10 Jul 2019 //
FIERCE BIOTECH
Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer
08 Jul 2019 //
BIOSPACE
DotLab nets $10M for its blood test to diagnose endometriosis
02 Jul 2019 //
FIERCE BIOTECH
New InvgClinical Data for Ipsen’s Oncology Products in 11 Solid Tumor
24 May 2019 //
BUSINESSWIRE
Armas Pharma Continues to Add to Portfolio Launch of IInd Oncology Injectable
07 May 2019 //
PR NEWSWIRE
Shilpa Medicare`s Generic Irinotecan Hydrochloride Receives Approval in US
01 Jan 2019 //
FDA
Shilpa Medicare`s Generic Irinotecan Hydrochloride Receives Approval in US
31 Dec 2018 //
FDA
JIANGSU YEW Pharmaceutical Co. Ltd. Fails EDQM Inspection
15 Sep 2018 //
EDQM
Enforcement Report - Week of July 11, 2018
11 Jul 2018 //
FDA
Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles
17 Apr 2018 //
REUTERS
FDA Accepts Bristol-Myers Combo Application
28 Mar 2018 //
BIOSPACE
French pharma group Ipsen sees more asset purchases, U.S. growth
16 Feb 2018 //
REUTERS
Five drugs suspended after factory inspection
25 Oct 2017 //
FDA
Merrimack names Drummond as head of research unit
17 Apr 2017 //
FIERCE BIOTECH
NICE knocks-back Shire`s pancreatic cancer drug Onivyde
28 Mar 2017 //
PMLIVE
SMC welcomes Roche’s Gazyvaro but rejects Shire’s Onivyde
14 Mar 2017 //
PHARMATIMES
Sanofi Genzyme (SNY) Exec Jumps Ship to Helm Merrimack (MACK)
18 Jan 2017 //
BIOSPACE
NICE Rejects Shire’s Pancreatic Cancer Drug
17 Nov 2016 //
PHARMATIMES
Shire wins EU licence for pancreatic cancer drug Onivyde
18 Oct 2016 //
PM LIVE
ONIVYDE Receives +ve CHMP Opinion for Treatment of Patients with Adenocarcinoma
26 Jul 2016 //
PR NEWSWIRE
Merrimack, Baxalta Announce Initiation of Phase 1 Study of MM-151 with ONIVYDE
19 May 2016 //
PR NEWSWIRE
PharmaEngine Announces Korean Ministry of Food and Drug Safety Accepted ONIVYDE
10 May 2016 //
PR NEWSWIRE
Camptosar ANDA Approval Adds More Competition for Generic Market
09 May 2016 //
TWOFOUR INSIGHT
3SBio gets China FDA IND nod for PEG-irinotecan candidate
07 Mar 2016 //
FIERCE PHARMA ASIA
CHMP Issues Opinion for LONSURF for Refractory Metastatic Colorectal Cancer
29 Feb 2016 //
PR NEWSWIRE
Updated Data Shows ONIVYDE® Combination Regimen Increased One Year Survival
19 Jan 2016 //
PR NEWS WIRE
Merrimack to Present Overall Survival Analysis of Ph3 NAPOLI-1 Study of ONIVYDE
11 Jan 2016 //
PR NEWS WIRE
Ipsen buys cancer business from stripped down Merrimack
09 Jan 2016 //
PMLIVE
Merrimack & Baxalta Announce Publication of ONIVYDE NAPOLI-1 Study in Lancet
23 Nov 2015 //
PR NEWSWIRE
AqVida crowns innovative first decade with robotic filling breakthrough
23 Sep 2015 //
PRESS RELEASE
Taiwan`s PharmEngine initiates clinical trial of chemotherapy drug
05 May 2015 //
BIOSPECTRUM ASIA
12 cancer drugs may come under price control
05 May 2015 //
THE INDIAN EXPRESS
